ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for atrial fibrillation and
other cardiovascular diseases, today announced that Dr. Michael Bristow,
President and Chief Executive Officer, will be a featured panelist at
the
New Paradigms to Fund & Move Drug Development, January
11-12, 2012 in San Francisco. Dr. Bristow will be a panelist on the
session “Plasma and Imaging Biomarkers that Drive Value and Improve
Success Rates,” Thursday, January 12, 2012 at 11:15 a.m. Pacific.
More information about the conference is available at:
http://www.theconferenceforum.org/NewParadigms-Overview.html.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies
for cardiovascular diseases. The Company's lead product candidate,
Gencaro
TM (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for atrial fibrillation. ARCA has identified common genetic
variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA is collaborating with
Laboratory Corporation of America to develop the companion genetic test
for Gencaro. For more information please visit
www.arcabiopharma.com.
Safe Harbor Statement
This press release and the anticipated presentation contain
"forward-looking statements" for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements regarding the ability of
genetic variations to predict individual patient response to Gencaro and
the potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment. Such statements are based on
management's current expectations and involve risks and uncertainties.
Actual results and performance could differ materially from those
projected in the forward-looking statements as a result of many factors,
including, without limitation, the risks and uncertainties associated
with: the Company's financial resources and whether they will be
sufficient to meet the Company's business objectives and operational
requirements; the protection and market exclusivity provided by the
Company’s intellectual property; risks related to the drug discovery and
the regulatory approval process; and, the impact of competitive products
and technological changes. These and other factors are identified and
described in more detail in ARCA’s filings with the SEC, including
without limitation the Company’s annual report on Form 10-K for the year
ended December 31, 2010 and subsequent filings. The Company disclaims
any intent or obligation to update these forward-looking statements.
Copyright Business Wire 2012
